Key facts
- What it is: a chronic metabolic condition marked by high blood glucose from insulin resistance plus declining insulin secretion.
- Incretin link: the incretin effect — the extra insulin released after an oral glucose load — is reduced in type 2 diabetes.
- Drug classes involved: GLP-1 receptor agonists and dual GIP/GLP-1 agonists such as tirzepatide.
- Dual effect: these drugs lower glucose and body weight together, with a low intrinsic risk of hypoglycaemia.
- Cardiovascular evidence: LEADER (liraglutide, HR 0.87), SUSTAIN-6 (semaglutide, HR 0.74) and REWIND (dulaglutide, HR 0.88) all reduced major adverse cardiovascular events versus placebo.
- Head-to-head: in SURPASS-2, tirzepatide beat semaglutide 1 mg on HbA1c and weight in type 2 diabetes.
- Two indications: diabetes and obesity are approved separately, often under different brands and doses.
What type 2 diabetes is
Type 2 diabetes is a chronic condition in which blood glucose runs persistently high because the body both resists insulin and, over time, produces too little of it. It is by far the most common form of diabetes, and it develops gradually — often quietly — against a background of excess body weight, physical inactivity and genetic predisposition.
Two failures overlap. In insulin resistance, muscle, liver and fat tissue respond weakly to insulin, so more of the hormone is needed to move glucose out of the blood. In parallel, the insulin-producing beta cells of the pancreas gradually lose the capacity to keep up. Early on the pancreas compensates by working harder; as the disease progresses, that compensation fades and glucose climbs. This is why type 2 diabetes tends to need escalating treatment over years, and why drugs that support insulin secretion and reduce the metabolic load are useful.
Type 2 diabetes and the incretin system
One of the tidiest windows into type 2 diabetes is the incretin effect. When you swallow glucose, your pancreas releases substantially more insulin than it does when the same amount of glucose is delivered directly into a vein. The difference is the incretin effect, and it exists because the gut releases hormones — glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) — that prime the pancreas to respond to an incoming meal.
In type 2 diabetes this amplification is blunted. The post-meal insulin surge that a healthy pancreas produces is smaller, contributing to the high glucose readings that follow eating. Researchers have long debated how much of that is reduced hormone secretion versus reduced responsiveness to the hormones, but the practical upshot is clear: the incretin axis under-performs. That observation is what turned GLP-1 into a drug target. If the natural signal is weak, a longer-acting molecule that switches on the same receptor can stand in for it.
How GLP-1 and dual agonists improve glucose and weight
GLP-1 receptor agonists are engineered versions of the natural hormone, modified to resist rapid breakdown so they last hours or a week rather than minutes. Once bound to the GLP-1 receptor, they do several things at once. They increase insulin secretion — but only when blood glucose is elevated, which is why they rarely cause hypoglycaemia on their own. They suppress glucagon, the hormone that raises glucose. They slow gastric emptying, blunting the post-meal spike. And they act on appetite centres in the brain, reducing hunger and food intake. That last effect is why the same molecule that treats diabetes also produces meaningful weight loss.
Because these actions all pull glucose in the same direction while also lowering body weight, GLP-1 agonists sit in a different niche from older agents. A drug that lowers HbA1c and takes weight off, rather than adding it, is attractive in a condition so tightly bound up with excess weight. Dual agonists take the idea further by engaging a second incretin receptor, GIP, alongside GLP-1 — the rationale being that recruiting both arms of the incretin system might amplify the metabolic benefit. Our summaries of semaglutide and the wider class of GLP-1 receptor agonists go deeper on the individual molecules.
Cardiovascular-outcome evidence
Lowering HbA1c is worth little if it does not translate into fewer of the events that actually harm people with diabetes — heart attacks, strokes and cardiovascular death. After an earlier era of diabetes drugs that improved glucose numbers without proving they helped hearts, regulators began requiring dedicated cardiovascular-outcome trials. Several GLP-1 agonists have now cleared that bar.
| Trial | Drug | Population | Primary MACE result vs placebo |
|---|---|---|---|
| LEADER | Liraglutide | Type 2 diabetes at high cardiovascular risk | Hazard ratio 0.87 (fewer major adverse cardiovascular events) |
| SUSTAIN-6 | Semaglutide | Type 2 diabetes at high cardiovascular risk | Hazard ratio 0.74 |
| REWIND | Dulaglutide | Type 2 diabetes, mostly primary prevention | Hazard ratio 0.88 |
In LEADER, once-daily liraglutide reduced the composite of cardiovascular death, non-fatal heart attack and non-fatal stroke versus placebo in people with type 2 diabetes at high cardiovascular risk. SUSTAIN-6 showed a comparable direction with once-weekly semaglutide, and its result helped establish that the benefit was not unique to a single molecule. REWIND stood out because most of its participants did not have established cardiovascular disease at entry, so dulaglutide's reduction in events extended the evidence toward a broader, lower-risk diabetes population.
Two cautions keep this honest. First, the class is not uniform — cardiovascular benefit has to be demonstrated for each drug, not assumed from the label. Second, these were trials in people with diabetes; the separate question of cardiovascular benefit in obesity without diabetes was tested in a different study, summarised in our SELECT trial explainer.
Dual agonists and head-to-head data
The dual GIP/GLP-1 agonist tirzepatide raised an obvious question: does adding the GIP receptor to the GLP-1 mechanism actually do more in practice? The SURPASS-2 trial answered it directly by pitting tirzepatide against semaglutide 1 mg once weekly in adults with type 2 diabetes. Tirzepatide produced greater reductions in HbA1c and in body weight than semaglutide in that comparison — one of the clearest head-to-head signals that engaging both incretin receptors can outperform a single-receptor agonist on these measures.
Head-to-head trials like this are unusual and valuable, because most drugs are compared only against placebo. A broader review of GLP-1 receptor agonists across such studies helps place any single result in context rather than treating one trial as the final word. What SURPASS-2 does not settle is long-term cardiovascular outcomes for tirzepatide against semaglutide; a difference in HbA1c and weight is not the same as a difference in heart attacks, and that is a separate evidentiary question. You can compare the two molecules side by side in our semaglutide summary and the broader peptides for weight loss evidence map.
Diabetes versus obesity indications
It is easy to blur the two uses because the molecules overlap, but the distinction matters. A GLP-1 or dual agonist can be approved for type 2 diabetes, for chronic weight management, or for both — and each indication rests on its own set of trials in the relevant population. Semaglutide, for instance, is marketed for diabetes and, at a higher maintenance dose under a different brand, for weight management. The diabetes approval does not automatically license the obesity use, and vice versa; regulators require evidence specific to each.
Practically, that means the "same drug" can appear under different brand names, at different doses, with different approved populations and different insurance rules. For a reader trying to make sense of the landscape, the useful mental model is: one incretin mechanism, several molecules, and two related but separately governed clinical uses. Which use — if any — applies to a given individual is a prescription decision, weighed with a clinician against personal history and other conditions. For the wider map of which drugs carry which evidence, see the pillar guide on peptides for weight loss and the full research library.
Frequently asked questions
What is the incretin effect and why does it matter in type 2 diabetes?
The incretin effect is the way gut hormones, chiefly GLP-1 and GIP, boost insulin release after eating so that an oral glucose load triggers more insulin than the same glucose given intravenously. In type 2 diabetes this amplification is blunted. Restoring GLP-1 signalling with a receptor agonist is one way to prompt more glucose-dependent insulin release, which is a core reason these drugs are used in the condition.
How do GLP-1 receptor agonists lower blood sugar?
GLP-1 receptor agonists mimic the natural hormone GLP-1. They increase insulin secretion when glucose is high, suppress glucagon, and slow gastric emptying so glucose enters the blood more gradually. They also act on appetite pathways in the brain, which reduces food intake. Because the insulin effect is glucose-dependent, GLP-1 agonists used on their own carry a low risk of hypoglycaemia compared with insulin or sulfonylureas.
Do GLP-1 drugs for diabetes also reduce heart attacks and strokes?
Several cardiovascular-outcome trials in people with type 2 diabetes have shown a benefit. LEADER reported that liraglutide lowered major adverse cardiovascular events versus placebo (hazard ratio 0.87), SUSTAIN-6 showed a reduction with semaglutide (hazard ratio 0.74), and REWIND showed a reduction with dulaglutide (hazard ratio 0.88) in a population that was mostly primary prevention. Not every drug in the class has proven this, so the benefit is judged trial by trial.
What is the difference between a GLP-1 agonist and a dual GIP/GLP-1 agonist?
A GLP-1 agonist activates a single incretin receptor, the GLP-1 receptor. A dual agonist such as tirzepatide activates both the GLP-1 receptor and the GIP receptor. In the SURPASS-2 head-to-head trial, tirzepatide produced greater reductions in HbA1c and body weight than semaglutide 1 mg once weekly in people with type 2 diabetes. Adding the GIP mechanism is one explanation offered for the larger effect, though the trial measured outcomes rather than proving the mechanism.
Are the diabetes and obesity uses of these drugs the same?
They overlap in molecule but differ in indication, and often in brand and dose. Semaglutide is marketed for type 2 diabetes and, at a different dose, for chronic weight management, under separate brand names. Regulators approve each use on the strength of trials in that population, so a drug proven in diabetes is not automatically approved for obesity, and vice versa. Which use applies to a given person is a prescription decision made with a clinician.
Does taking a GLP-1 drug cure type 2 diabetes?
No. GLP-1 receptor agonists and dual agonists manage type 2 diabetes by improving glucose control and, in several trials, cardiovascular risk, but they do not cure the condition. Blood-sugar and weight benefits are tied to continued treatment and lifestyle measures, and glucose control tends to drift back if treatment stops. This page is educational and not medical advice.
Sources
This overview traces to peer-reviewed cardiovascular-outcome and head-to-head trials and a class review:
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — New England Journal of Medicine, 2016; PubMed 27633186.
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER) — New England Journal of Medicine, 2016; PubMed 27295427.
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) — Lancet, 2019; PubMed 31189511.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — New England Journal of Medicine, 2021; PubMed 34170647.
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies — Therapeutic Advances in Endocrinology and Metabolism, 2021; PubMed 33767808.
- Condition reference record: Type 2 diabetes.